Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy

Journal of Infectious Diseases

Volumn 208, Issue 5, 2013, Pages 839-846

  Tobian, Aaron A R ^a,f   Grabowski, Mary K ^c   Serwadda, David ^f,g   Newell, Kevin ^d   Ssebbowa, Paschal ^f   Franco, Veronica ^b   Nalugoda, Fred ^f   Wawer, Maria J ^c,f   Gray, Ronald H ^c,f   Quinn, Thomas C ^b,e   Reynolds, Steven J ^b,c,e,f  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^g MAKERERE UNIVERSITY   (Uganda)

Author keywords

acyclovir; herpes simplex virus type 2 (HSV 2); human immunodeficiency virus (HIV); immune reconstitution inflammatory syndrome (IRIS); reactivation; Uganda

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PLACEBO; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENITAL HERPES; GENITAL ULCER; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TREATMENT OUTCOME; UGANDA; VIRUS DETECTION; VIRUS REACTIVATION; VIRUS SHEDDING;

ACYCLOVIR; HERPES SIMPLEX VIRUS TYPE 2 (HSV-2); HUMAN IMMUNODEFICIENCY VIRUS (HIV); IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS); REACTIVATION; UGANDA;

ACYCLOVIR; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLACEBOS; UGANDA; VAGINA; VIRUS ACTIVATION; VIRUS SHEDDING; YOUNG ADULT;

EID: 84881652714     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit252     Document Type: Article

References (34)

1. Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007; 370: 2127-37.
2. Tobian AA, Quinn TC. Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Curr Opin HIVAIDS 2009; 4:294-9.
3. Tobian AA, Ssempijja V, Kigozi G, et al. Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS 2009; 23:1589-94.
4. Suntoke TR, Hardick A, Tobian AA, et al. Evaluation of multiplex realtime PCR for detection of H. ducreyi, T. pallidum, HSV-1, and HSV-2 in the diagnosis of genital ulcer disease in Rakai District, Uganda. Sex Transm Infect 2009; 85:97-101.
5. Tobian AAR, Charvat B, Ssempijja V, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infections among men in Rakai, Uganda. J Infect Dis 2009; 199:945-9.
6. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids 2006; 20:73-83.
7. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435-45.
8. Rebbapragada A, Wachihi C, Pettengell C, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. Aids 2007; 21:589-98.
9. Holmberg SD, Stewart JA, Gerber AR, et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. Jama 1988; 259:1048-50.
10. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of Herpes Simplex Suppression on Incidence of HIV amongWomen in Tanzania. N Engl J Med 2008; 358:1560-71.
11. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-19.
12. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-39.
13. Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375:824-33.
14. Reynolds SJ, Makumbi F, Newell K, et al. Daily acyclovir to prevent disease progression among HIV-1/HSV-2 co-infected individuals: a randomized, double-blinded placebo controlled trial in Rakai, Uganda. Lancet Infect Dis 2012; 12:441-8.
15. McClelland RS, Wang CC, Overbaugh J, et al. Association between cervical shedding of herpes simplex virus and HIV-1. Aids 2002; 16:2425-30.
16. Serwadda D, Gray RH, Sewankambo NK, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis 2003; 188:1492-7.
17. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107-15.
18. Couppie P, Sarazin F, Clyti E, et al. Increased incidence of genital herpes after HAART initiation: a frequent presentation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients. AIDS Patient Care STDS 2006; 20:143-5.
19. Graham SM, Masese L, Gitau R, et al. Increased risk of genital ulcer disease in women during the first month after initiating antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52:600-3.
20. Mayaud P, Nagot N, Konate I, et al. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex Transm Infect 2008; 84:332-7.
21. Posavad CM, Wald A, Kuntz S, et al. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J Infect Dis 2004; 190:693-6.
22. Ameli N, Bacchetti P, Morrow RA, et al. Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations. AIDS 2006; 20:1051-8.
23. Laeyendecker O, Henson C, Gray RH, et al. Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol 2004; 42:1794-6.
24. Jerome KR, Huang ML, Wald A, Selke S, Corey L. Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. J Clin Microbiol 2002; 40:2609-11.
25. Magaret AS, Wald A, Huang ML, Selke S, Corey L. Optimizing PCR positivity criterion for detection of herpes simplex virus DNA on skin and mucosa. J Clin Microbiol 2007; 45:1618-20.
26. Tuboi SH, Pacheco AG, Harrison LH, et al. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings. J Acquir Immune Defic Syndr 2010; 53:70-7.
27. Tronstein E, Johnston C, Huang ML, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011; 305:1441-9.
28. Johnston C, Saracino M, Kuntz S, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 2012; 379: 641-7.
29. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333:770-5.
30. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and metaanalysis. Lancet Infect Dis 2010; 10:251-61.
31. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009; 48:101-7.
32. Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008; 59:381-95.
33. Novak RM, Richardson JT, Buchacz K, et al. Immune reconstitution inflammatory syndrome: incidence and implications for mortality. AIDS 2012; 26:721-30.
34. Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume JC, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol 2007; 57:238-46.